Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial

NCT06236295 is registered in ClinicalTrials.gov with Shanghai Hengrui Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06236295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06236295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial
Lead sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
February 20, 2024
Completion date
November 13, 2025
Enrollment
303 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

secondary hyperparathyroidism (shpt) in subjects with chronic kidney disease (ckd) on hemodialysis